CompletedPhase 1NCT03387020
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Studying Atypical teratoid rhabdoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pediatric Brain Tumor Consortium
- Principal Investigator
- Mariko D. DeWire-Schottmiller, MDPediatric Brain Tumor Consortium
- Intervention
- Everolimus(drug)
- Enrollment
- 22 enrolled
- Eligibility
- 1-21 years · All sexes
- Timeline
- 2018 – 2020
Study locations (12)
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Lucile Packard Children Hospital Stanford University, Palo Alto, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States
- Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
- Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
- St. Jude Children Research Hospital, Memphis, Tennessee, United States
- Texas Children's Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03387020 on ClinicalTrials.govOther trials for Atypical teratoid rhabdoid tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06465199Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasMilton S. Hershey Medical Center
- RECRUITINGEARLY PHASE1NCT07017816A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Children's National Research Institute
- RECRUITINGPHASE2NCT06622941Study to ONO-4538 in Patients With Rhabdoid TumorOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06193759Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)Children's National Research Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD
- RECRUITINGPHASE1NCT05835687Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS TumorsSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05286801Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT06853080Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid TumorsTaipei Medical University